Wave Life Sciences is expected to report Q3 2026 revenue of $4.51 million and an EPS loss of $0.34, with its current price of $3.19 trading well below the $21.53 average analyst target.
Investors are primarily focused on clinical updates for WVE-007, an RNA-targeted obesity candidate, and the company's timeline for filing a New Drug Application for WVE-N531 in Duchenne muscular dystrophy.
The company recently validated its PRISM platform with successful RNA editing data, which analysts believe could catalyze further milestones from its GSK collaboration. Management is also expected to provide updates on its cash runway, which currently extends into the second quarter of 2027.